[New therapeutic trends in benign hypertrophy of the prostate].
Chatelain
C
C
D000317:Adrenergic alpha-Antagonists / Q000627:therapeutic use; D017115:Catheter Ablation; D004598:Electrosurgery; D004724:Endoscopy; D004791:Enzyme Inhibitors / Q000627:therapeutic use; D005069:Evaluation Studies as Topic; D018120:Finasteride / Q000627:therapeutic use; D006358:Hot Temperature / Q000627:therapeutic use; D006801:Humans; D053685:Laser Therapy; D008297:Male; D008872:Microwaves / Q000627:therapeutic use; D008517:Phytotherapy; D011446:Prospective Studies; D011468:Prostatectomy; D011470:Prostatic Hyperplasia / Q000601:surgery / Q000628:therapy*; D019919:Prosthesis Implantation; D016032:Randomized Controlled Trials as Topic; D014464:Ultrasonic Therapy
D000317:Adrenergic alpha-Antagonists; D004791:Enzyme Inhibitors; D018120:Finasteride
Orientations thérapeutiques nouvelles dans l'hypertrophie bénigne de la prostate.